Roberto Veronese is an influential digital health and biotech product leader. Building on over 10 years of experience in genomics, AI applied to precision medicine, and consumer digital health, Mr. Veronese advises early- and mid-stage startups on market research, product strategy, customer experience design, and clinical integrations. Those companies include Artera, ventures backed by Khosla Ventures, Y Combinator, and more. Notably, through a multiyear engagement with GRAIL, he provided critical leadership in the launch of their pioneering multi- cancer early detection test analyzing methylation patterns of cell-free DNA (cfDNA) in the bloodstream.

As Vice President of Product and Design at Helix, Mr. Veronese contributed to the development of their direct-to-consumer genomics strategy and clinical product portfolio. He helped drive the company’s successful shift into population genomics, supporting partnerships with renowned institutions like Mayo Clinic and Renown Health to combine patient genetic and electronic health record data for research and population screening purposes.

Previously, Mr. Veronese honed his strategic skills leading product teams at global innovation consulting firms such as Method, frog/Capgemini, and Value Partners Group. Across these roles, he became a trusted strategic partner to digital health and biotech leaders on driving market adoption and achieving product-market fit.

Currently based in San Francisco, Mr. Veronese lends his expertise to select product advisory roles and collaborations dedicated to advancing precision medicine’s potential. He holds executive education credentials in AI product development, healthcare management, telehealth, and digital therapeutics from MIT, Yale School of Management, Stanford School of Medicine, and Columbia Business School respectively, in addition to a BA and MA in Philosophy from the prestigious University of Padova in Italy.